Myriad Genetics, Inc. (MYGN)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myriad Genetics, Inc. (“Myriad” or “the Company”) (NASDAQ: MYGN). Investors who purchased Myriad securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Myriad has violated federal securities laws.
Myriad Investigation Details
On July 30, 2026, Myriad Genetics reported Q2 2026 revenue of approximately $190.7 million, down roughly 11% year-over-year and 7% to 8% below Wall Street consensus of approximately $206–$208 million. Simultaneously, the Company cut its full-year 2026 revenue guidance to $770–$790 million from approximately $860–$880 million, lowered gross margin expectations, and suspended its adjusted EBITDA guidance entirely — which had previously been set at $37–$49 million. Management attributed the shortfall to reimbursement pressure, collections issues, lower average revenue per test, and weaker prenatal performance. Following this news, Myriad’s stock price dropped. Notably, as recently as May 5, 2026, the Company had reiterated its full-year 2026 revenue guidance of $860–$880 million — a range that was slashed by approximately $90 million at the midpoint just three months later.
What’s Next for Myriad Investors?
If you are aware of any facts relating to this investigation or purchased Myriad securities, you can assist this investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911
No Cost to Myriad Investors
We, Bronstein, Gewirtz & Grossman, LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman, LLC For Myriad Securities Investigation?
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace,” said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.
Follow us for updates on LinkedIn, X, Facebook, or Instagram.
Contact Info
Peretz Bronstein, Esq. or Nathan Miller
Bronstein, Gewirtz & Grossman, LLC
917-590-0911 | [email protected]
Attorney advertising.
Prior results do not guarantee similar outcomes.